Tris-DBA pharmaceutical composition and its use of for treating IgA nephropathy
Category: Pharmaceutical
Exhibitor: NATIONAL DEFENSE MEDICAL CENTER
Booth No: R1122
Characteristic
IgA nephropathy (IgAN) is the most common primary glomerular disorder, featuring predominant glomerular IgA immune-complexes (ICs) deposition in the kidney. However, the current treatment for IgAN is still insufficient. Our discovery shows that Tris (Dibenzylideneacetone) dipalladium (Tris DBA), a small molecule palladium complex, improved IgAN mice by blunting the activating signal of NLRP3 inflammasome through SIRT1- and SIRT3-mediated autophagy induction.
Other Products
Products you may be interested in
Highest Rated Products